AVBP (ArriVent BioPharma) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Asset Impairment Charge?

ArriVent BioPharma's Asset Impairment Charge for the three months ended in Dec. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

ArriVent BioPharma Asset Impairment Charge Historical Data

The historical data trend for ArriVent BioPharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Asset Impairment Charge Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

ArriVent BioPharma Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Asset Impairment Charge	Get a 7-Day Free Trial						-	-	-	-	-

ArriVent BioPharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

ArriVent BioPharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://www.arrivent.com

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.